Keratin 17: A Critical Player in the Pathogenesis of Psoriasis

Medicinal Research Reviews

Volumn 34, Issue 2, 2014, Pages 438-454

  Jin, Liang ^a   Wang, Gang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Immunoregulation; Keratin 17; Keratinocytes; Positive feedback loop; Psoriasis

Indexed keywords

IMMUNOREGULATION; KERATIN 17; KERATINOCYTES; POSITIVE FEEDBACK LOOP; PSORIASIS;

ANIMALS; HUMANS; KERATIN-17; PSORIASIS;

EID: 84895064450     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21291     Document Type: Article

References (101)

1. Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis-Part I: Clinical and pathologic concepts. J Allergy Clin Immunol 2011;127(5):1110-1118.
2. Perera GK, Di Meglio P, Nestle FO. Psoriasis. Annu Rev Pathol 2012;7:385-422.
3. Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol 2001;26(4):314-320.
4. McKee PH, Calonje E, Granter SR. Pathology of the Skin : With Clinical Correlations. Philadelphia: Elsevier Mosby; 2005. 195 p.
5. Bolognia J, Jorizzo JL, Schaffer JV. Dermatology. New York: Saunders; 2012. 153 p.
6. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361(5):496-509.
7. Roberson ED, Bowcock AM. Psoriasis genetics: Breaking the barrier. Trends Genet 2010;26(9):415-423.
8. Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis-Part II: Immune cell subsets and therapeutic concepts. J Allergy Clin Immunol 2011;127(6):1420-1432.
9. Gilliet M, Lande R. Antimicrobial peptides and self-DNA in autoimmune skin inflammation. Curr Opin Immunol 2008;20(4):401-407.
10. Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. Skin immune sentinels in health and disease. Nat Rev Immunol 2009;9(10):679-691.
11. Wilson CL, Deane D, Wojnarowska F, Lane EB, Leigh IM. Follicular keratin expression in normal and psoriatic scalp (abstr). J Invest Dermatol 1990;95:495.
12. Bockelmann R, Horn T, Gollnick H, Bonnekoh B. Interferon-gamma-dependent in vitro model for the putative keratin 17 autoimmune loop in psoriasis: Exploration of pharmaco- and gene-therapeutic effects. Skin Pharmacol Physiol 2005;18(1):42-54.
13. Shen Z, Wang G, Fan JY, Li W, Liu YF. HLA DR B1*04, *07-restricted epitopes on Keratin 17 for autoreactive T cells in psoriasis. J Dermatol Sci 2005;38(1):25-39.
14. Szeverenyi I, Cassidy AJ, Chung CW, Lee BT, Common JE, Ogg SC, Chen H, Sim SY, Goh WL, Ng KW, Simpson JA, Chee LL, Eng GH, Li B, Lunny DP, Chuon D, Venkatesh A, Khoo KH, McLean WH, Lim YP, Lane EB. The Human Intermediate Filament Database: Comprehensive information on a gene family involved in many human diseases. Hum Mutat 2008;29(3):351-360.
15. Omary MB, Coulombe PA, McLean WH. Intermediate filament proteins and their associated diseases. N Engl J Med 2004;351(20):2087-2100.
16. Porter RM, Lane EB. Phenotypes, genotypes and their contribution to understanding keratin function. Trends Genet 2003;19(5):278-285.
17. Chamcheu JC, Siddiqui IA, Syed DN, Adhami VM, Liovic M, Mukhtar H. Keratin gene mutations in disorders of human skin and its appendages. Arch Biochem Biophys 2011;508(2):123-137.
18. Windoffer R, Beil M, Magin TM, Leube RE. Cytoskeleton in motion: The dynamics of keratin intermediate filaments in epithelia. J Cell Biol 2011;194(5):669-678.
19. Schweizer J, Bowden PE, Coulombe PA, Langbein L, Lane EB, Magin TM, Maltais L, Omary MB, Parry DA, Rogers MA, Wright MW. New consensus nomenclature for mammalian keratins. J Cell Biol 2006;174(2):169-174.
20. Karantza V. Keratins in health and cancer: More than mere epithelial cell markers. Oncogene 2011;30(2):127-138.
21. Gu LH, Coulombe PA. Keratin function in skin epithelia: A broadening palette with surprising shades. Curr Opin Cell Biol 2007;19(1):13-23.
22. McGowan KM, Coulombe PA. Onset of keratin 17 expression coincides with the definition of major epithelial lineages during skin development. J Cell Biol 1998;143(2):469-486.
23. Troyanovsky SM, Guelstein VI, Tchipysheva TA, Krutovskikh VA, Bannikov GA. Patterns of expression of keratin 17 in human epithelia: Dependency on cell position. J Cell Sci 1989;93(Pt 3):419-426.
24. Kurokawa I, Takahashi K, Moll I, Moll R. Expression of keratins in cutaneous epithelial tumors and related disorders-Distribution and clinical significance. Exp Dermatol 2011;20(3):217-228.
25. De Berker D, Wojnarowska F, Sviland L, Westgate GE, Dawber RP, Leigh IM. Keratin expression in the normal nail unit: Markers of regional differentiation. Br J Dermatol 2000;142(1):89-96.
26. Bragulla HH, Homberger DG. Structure and functions of keratin proteins in simple, stratified, keratinized and cornified epithelia. J Anat 2009;214(4):516-559.
27. Tong X, Coulombe PA. A novel mouse type I intermediate filament gene, keratin 17n (K17n), exhibits preferred expression in nail tissue. J Invest Dermatol 2004;122(4):965-970.
28. McLean WH, Rugg EL, Lunny DP, Morley SM, Lane EB, Swensson O, Dopping-Hepenstal PJ, Griffiths WA, Eady RA, Higgins C, Et A. Keratin 16 and keratin 17 mutations cause pachyonychia congenita. Nat Genet 1995;9(3):273-278.
29. Zang D, Zhou C, He M, Ma X, Zhang J. A novel mutation (p.Arg94Gly) of keratin 17 in a Chinese family with steatocystoma multiplex. Eur J Dermatol 2011;21(1):142-144.
30. McGowan KM, Tong X, Colucci-Guyon E, Langa F, Babinet C, Coulombe PA. Keratin 17 null mice exhibit age- and strain-dependent alopecia. Genes Dev 2002;16(11):1412-1422.
31. Tong X, Coulombe PA. Keratin 17 modulates hair follicle cycling in a TNFalpha-dependent fashion. Genes Dev 2006;20(10):1353-1364.
32. Kim S, Wong P, Coulombe PA. A keratin cytoskeletal protein regulates protein synthesis and epithelial cell growth. Nature 2006;441(7091):362-365.
33. Hughes BR, Morris C, Cunliffe WJ, Leigh IM. Keratin expression in pilosebaceous epithelia in truncal skin of acne patients. Br J Dermatol 1996;134(2):247-256.
34. Sugisaki H, Yamanaka K, Kakeda M, Kitagawa H, Tanaka K, Watanabe K, Gabazza EC, Kurokawa I, Mizutani H. Increased interferon-gamma, interleukin-12p40 and IL-8 production in Propionibacterium acnes-treated peripheral blood mononuclear cells from patient with acne vulgaris: Host response but not bacterial species is the determinant factor of the disease. J Dermatol Sci 2009;55(1):47-52.
35. Depianto D, Kerns ML, Dlugosz AA, Coulombe PA. Keratin 17 promotes epithelial proliferation and tumor growth by polarizing the immune response in skin. Nat Genet 2010;42(10):910-914.
36. Proby CM, Churchill L, Purkis PE, Glover MT, Sexton CJ, Leigh IM. Keratin 17 expression as a marker for epithelial transformation in viral warts. Am J Pathol 1993;143(6):1667-1678.
37. Mcnairn AJ, Guasch G. Epithelial transition zones: Merging microenvironments, niches, and cellular transformation. Eur J Dermatol 2011;21(Suppl 2):21-28.
38. Pan X, Kane LA, Van Eyk JE, Coulombe PA. Type I keratin 17 protein is phosphorylated on serine 44 by p90 ribosomal protein S6 kinase 1 (RSK1) in a growth- and stress-dependent fashion. J Biol Chem 2011;286(49):42403-42413.
39. Ide M, Kato T, Ogata K, Mochiki E, Kuwano H, Oyama T. Keratin 17 expression correlates with tumor progression and poor prognosis in gastric adenocarcinoma. Ann Surg Oncol 2012;19(11):3506-3514.
40. Fan J, Shen Z, Wang G, Yang H, Liu Y. Secretory expression of human ScFv against keratin in Pichia pastoris and its effects on cultured keratinocytes. Arch Dermatol Res 2009;301(5):367-372.
41. Shen Z, Chen L, Liu YF, Gao TW, Wang G, Fan XL, Fan JY, Fan PS, Li CY, Liu B, Dang YP, Li CX. Altered keratin 17 peptide ligands inhibit in vitro proliferation of keratinocytes and T cells isolated from patients with psoriasis. J Am Acad Dermatol 2006;54(6):992-1002.
42. de Jong EM, van Vlijmen IM, van Erp PE, Ramaekers FC, Troyanovski SM, van de Kerkhof PC. Keratin 17: A useful marker in anti-psoriatic therapies. Arch Dermatol Res 1991;283(7):480-482.
43. Leigh IM, Navsaria H, Purkis PE, McKay IA, Bowden PE, Riddle PN. Keratins (K16 and K17) as markers of keratinocyte hyperproliferation in psoriasis in vivo and in vitro. Br J Dermatol 1995;133(4):501-511.
44. Thewes M, Stadler R, Korge B, Mischke D. Normal psoriatic epidermis expression of hyperproliferation-associated keratins. Arch Dermatol Res 1991;283(7):465-471.
45. Bonnekoh B, Huerkamp C, Wevers A, Geisel J, Sebok B, Bange FC, Greenhalgh DA, Bottger EC, Krieg T, Mahrle G. Up-regulation of keratin 17 expression in human HaCaT keratinocytes by interferon-gamma. J Invest Dermatol 1995;104(1):58-61.
46. Shi X, Jin L, Dang E, Chang T, Feng Z, Liu Y, Wang G. IL-17A upregulates keratin 17 expression in keratinocytes through STAT1- and STAT3-dependent mechanisms. J Invest Dermatol 2011;131(12):2401-2408.
47. Zhang W, Dang E, Shi X, Jin L, Feng Z, Hu L, Wu Y, Wang G. The pro-inflammatory cytokine IL-22 up-regulates keratin 17 Expression in keratinocytes via STAT3 and ERK1/2. PLoS One 2012;7(7):e40797.
48. Bowcock AM, Krueger JG. Getting under the skin: The immunogenetics of psoriasis. Nat Rev Immunol 2005;5(9):699-711.
49. Mitra A, Fallen RS, Lima HC. Cytokine-based therapy in psoriasis. Clin Rev Allergy Immunol 2013;44(2):173-182.
50. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366(13):1190-1199.
51. Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EH, Baumgartner S. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012;366(13):1181-1189.
52. Johnson-Huang LM, Suarez-Farinas M, Pierson KC, Fuentes-Duculan J, Cueto I, Lentini T, Sullivan-Whalen M, Gilleaudeau P, Krueger JG, Haider AS, Lowes MA. A single intradermal injection of IFN-gamma induces an inflammatory state in both non-lesional psoriatic and healthy skin. J Invest Dermatol 2012;132(4):1177-1187.
53. Flohr T, Buwitt U, Bonnekoh B, Decker T, Bottger EC. Interferon-gamma regulates expression of a novel keratin class I gene. Eur J Immunol 1992;22(4):975-979.
54. Troyanovsky SM, Leube RE, Franke WW. Characterization of the human gene encoding cytokeratin 17 and its expression pattern. Eur J Cell Biol 1992;59(1):127-137.
55. Jiang CK, Flanagan S, Ohtsuki M, Shuai K, Freedberg IM, Blumenberg M. Disease-activated transcription factor: Allergic reactions in human skin cause nuclear translocation of STAT-91 and induce synthesis of keratin K17. Mol Cell Biol 1994;14(7):4759-4769.
56. Vogel U, Denecke B, Troyanovsky SM, Leube RE, Bottger EC. Transcriptional activation of psoriasis-associated cytokeratin K17 by interferon-gamma. Analysis of gamma-interferon activation sites. Eur J Biochem 1995;227(1-2):143-149.
57. Komine M, Freedberg IM, Blumenberg M. Regulation of epidermal expression of keratin K17 in inflammatory skin diseases. J Invest Dermatol 1996;107(4):569-575.
58. Wei L, Debets R, Hegmans JJ, Benner R, Prens EP. IL-1 beta and IFN-gamma induce the regenerative epidermal phenotype of psoriasis in the transwell skin organ culture system. IFN-gamma up-regulates the expression of keratin 17 and keratinocyte transglutaminase via endogenous IL-1 production. J Pathol 1999;187(3):358-364.
59. Gudmundsdottir AS, Sigmundsdottir H, Sigurgeirsson B, Good MF, Valdimarsson H, Jonsdottir I. Is an epitope on keratin 17 a major target for autoreactive T lymphocytes in psoriasis? Clin Exp Immunol 1999;117(3):580-586.
60. Johnston A, Gudjonsson JE, Sigmundsdottir H, Love TJ, Valdimarsson H. Peripheral blood T cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin-homing CD8(+) T cells. Clin Exp Immunol 2004;138(1):83-93.
61. Tervaert WC, Esseveld H. A study of the incidence of haemolytic streptococci in the throat in patients with psoriasis vulgaris, with reference to their role in the pathogenesis of this disease. Dermatologica 1970;140(5):282-290.
62. Leung DY, Travers JB, Giorno R, Norris DA, Skinner R, Aelion J, Kazemi LV, Kim MH, Trumble AE, Kotb M, Et A. Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis. J Clin Invest 1995;96(5):2106-2112.
63. Davison SC, Allen MH, Mallon E, Barker JN. Contrasting patterns of streptococcal superantigen-induced T-cell proliferation in guttate vs. chronic plaque psoriasis. Br J Dermatol 2001;145(2):245-251.
64. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370(9583):263-271.
65. Gudjonsson JE, Thorarinsson AM, Sigurgeirsson B, Kristinsson KG, Valdimarsson H. Streptococcal throat infections and exacerbation of chronic plaque psoriasis: A prospective study. Br J Dermatol 2003;149(3):530-534.
66. Smeesters PR, McMillan DJ, Sriprakash KS. The streptococcal M protein: A highly versatile molecule. Trends Microbiol 2010;18(6):275-282.
67. Valdimarsson H, Thorleifsdottir RH, Sigurdardottir SL, Gudjonsson JE, Johnston A. Psoriasis-as an autoimmune disease caused by molecular mimicry. Trends Immunol 2009;30(10):494-501.
68. Nozawa H, Kishibe K, Takahara M, Harabuchi Y. Expression of cutaneous lymphocyte-associated antigen (CLA) in tonsillar T-cells and its induction by in vitro stimulation with alpha-streptococci in patients with pustulosis palmaris et plantaris (PPP). Clin Immunol 2005;116(1):42-53.
69. Wang G, Liu YF, Li CY, Lu N, Gao TW, Hua B, Wang Y. Cloning and characterization of antikeratin human antibodies using a semisynthetic phage antibody library. Arch Dermatol Res 2004;296(6):270-277.
70. Fan L, Busser BW, Lifsted TQ, Oukka M, Lo D, Laufer TM. Antigen presentation by keratinocytes directs autoimmune skin disease. Proc Natl Acad Sci U S A 2003;100(6):3386-3391.
71. Steinman RM. Decisions about dendritic cells: Past, present, and future. Annu Rev Immunol 2012;30:1-22.
72. Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med 1999;341(24):1817-1828.
73. Morizane S, Yamasaki K, Muhleisen B, Kotol PF, Murakami M, Aoyama Y, Iwatsuki K, Hata T, Gallo RL. Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands. J Invest Dermatol 2012;132(1):135-143.
74. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, Cao W, Wang YH, Su B, Nestle FO, Zal T, Mellman I, Schroder JM, Liu YJ, Gilliet M. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007;449(7162):564-569.
75. Ganguly D, Chamilos G, Lande R, Gregorio J, Meller S, Facchinetti V, Homey B, Barrat FJ, Zal T, Gilliet M. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med 2009;206(9):1983-1994.
76. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, Abello MV, Novitskaya I, Pierson KC, Gonzalez J, Krueger JG, Lowes MA. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol 2009;129(1):79-88.
77. Eyerich S, Onken AT, Weidinger S, Franke A, Nasorri F, Pennino D, Grosber M, Pfab F, Schmidt-Weber CB, Mempel M, Hein R, Ring J, Cavani A, Eyerich K. Mutual antagonism of T cells causing psoriasis and atopic eczema. N Engl J Med 2011;365(3):231-238.
78. Quaglino P, Bergallo M, Ponti R, Barberio E, Cicchelli S, Buffa E, Comessatti A, Costa C, Terlizzi ME, Astegiano S, Novelli M, Cavallo R, Bernengo MG. Th1, Th2, Th17 and regulatory T cell pattern in psoriatic patients: Modulation of cytokines and gene targets induced by etanercept treatment and correlation with clinical response. Dermatology 2011;223(1):57-67.
79. Raychaudhuri SP. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol 2013;44(2):183-193.
80. Balato A, Unutmaz D, Gaspari AA. Natural killer T cells: An unconventional T-cell subset with diverse effector and regulatory functions. J Invest Dermatol 2009;129(7):1628-1642.
81. Gunther C, Carballido-Perrig N, Kaesler S, Carballido JM, Biedermann T. CXCL16 and CXCR6 are upregulated in psoriasis and mediate cutaneous recruitment of human CD8+ T cells. J Invest Dermatol 2012;132(3 Pt 1):626-634.
82. Res PC, Piskin G, de Boer OJ, van der Loos CM, Teeling P, Bos JD, Teunissen MB. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One 2010;5(11):e14108.
83. Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010;130(5):1373-1383.
84. Krueger JG, Fretzin S, Suarez-Farinas M, Haslett PA, Phipps KM, Cameron GS, McColm J, Katcherian A, Cueto I, White T, Banerjee S, Hoffman RW. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol 2012;130(1):145-154.
85. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, Ouyang W. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007;445(7128):648-651.
86. Ouyang W. Distinct roles of IL-22 in human psoriasis and inflammatory bowel disease. Cytokine Growth Factor Rev 2010;21(6):435-441.
87. Kryczek I, Wei S, Gong W, Shu X, Szeliga W, Vatan L, Chen L, Wang G, Zou W. Cutting edge: IFN-gamma enables APC to promote memory Th17 and abate Th1 cell development. J Immunol 2008;181(9):5842-5846.
88. Zielinski CE, Mele F, Aschenbrenner D, Jarrossay D, Ronchi F, Gattorno M, Monticelli S, Lanzavecchia A, Sallusto F. Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta. Nature 2012;484(7395):514-518.
89. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009;129(6):1339-1350.
90. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009;60(4):643-659.
91. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb AB, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61(3):451-485.
92. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010;62(1):114-135.
93. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58(5):826-850.
94. Radoja N, Komine M, Jho SH, Blumenberg M, Tomic-Canic M. Novel mechanism of steroid action in skin through glucocorticoid receptor monomers. Mol Cell Biol 2000;20(12):4328-4339.
95. Ramot Y, Paus R, Tiede S, Zlotogorski A. Endocrine controls of keratin expression. Bioessays 2009;31(4):389-399.
96. Radoja N, Diaz DV, Minars TJ, Freedberg IM, Blumenberg M, Tomic-Canic M. Specific organization of the negative response elements for retinoic acid and thyroid hormone receptors in keratin gene family. J Invest Dermatol 1997;109(4):566-572.
97. Bonnekoh B, Bockelmann R, Ambach A, Gollnick H. Dithranol and dimethylfumarate suppress the interferon-gamma-induced up-regulation of cytokeratin 17 as a putative psoriasis autoantigen in vitro. Skin Pharmacol Appl Skin Physiol 2001;14(4):217-225.
98. Tu HQ, Li XY, Tang MY, Gao JW, Xu LF, Chen ZQ, Gu H. Effects of tacrolimus on IFN-gamma signaling in keratinocytes: Possible mechanisms by which tacrolimus affects IFN-gamma-dependent skin inflammation. Eur J Dermatol 2011;21(1):22-31.
99. Takei-Taniguchi R, Imai Y, Ishikawa C, Sakaguchi Y, Nakagawa N, Tsuda T, Hollenberg MD, Yamanishi K. Interleukin-17- and protease-activated receptor 2-mediated production of CXCL1 and CXCL8 modulated by cyclosporine A, vitamin D3 and glucocorticoids in human keratinocytes. J Dermatol 2012;39(7):625-631.
100. Chang T, Sun L, Wang Y, Wang D, Li W, Li C, Gao T, Liu Y, Wang G. Inhibition of keratin 17 expression with antisense and RNAi strategies: Exploring novel therapy for psoriasis. Exp Dermatol 2011;20(7):555-560.
101. Milisavljevic V, Freedberg IM, Blumenberg M. Characterization of nuclear protein binding sites in the promoter of keratin K17 gene. Dna Cell Biol 1996;15(1):65-74.